INTERVIEW 'Microbiome to be game changer in immunotherapy'
Genome & Company CEO Pae Ji-soo speaks during an interview with The Korea Times at the newspaper's newsroom in Jung-gu, Seoul, Jan. 25. Korea Times photo by Kim Kang-minGenome & Company CEO pursues microbiome healthcare group By Nam Hyun-wooOne of the most rapidly growing sectors in the biopharmaceutical industry is microbiome medicine. Big name tycoons including Bill Gates and Mark Zuckerberg have already noticed the potential of microbiomes and either invested or donated money to businesses and research in this field, which is quickly evolving into a new money magnet. This is also the case of Genome & Company, a Korea-based microbiome biotech focusing on immuno-oncology drugs to treat cancers. In December last year, Genome & Company made its transfer to Korea's tech-heavy Kosdaq from the KONEX, the country's third bourse for startups and venture companies preparing to list on the junior bourse. In its Kosdaq debut trading session Dec. 23, the company's market cap reached 1.14 trillion won ($1 billion), which was the 44th-largest on the market.Pae Ji-soo, a medical d
Feb 15, 2021By Nam Hyun-woo